Daito Chemix reported ¥19.48bn in net sales, ¥894mn in ordinary income and ¥791mn in parent net profit for the year to March 2026. Sales were above the previous year's ¥18.64bn, and ordinary income edged up from ¥819mn.
The recovery story needs one small but important caveat. This was not the company's first profitable year after its downturn, because the filing excerpt also shows ¥820mn of parent net profit for the year to March 2025. The cleaner read-through is that Daito Chemix has stayed well clear of the ¥1.01bn parent-level loss it reported for the year to March 2024.
A separate internal control report filed the same day said the company's financial-reporting controls were effective as of March 31, 2026. The review covered Daito Chemix and all three group companies, focusing on processes tied to sales, receivables, inventory and tangible fixed assets, while adding impairment and tax-related processes for separate evaluation.
The public extract gives the headline numbers, but not a detailed management breakdown of what drove them. For now, the message is simpler: revenue rose, ordinary income improved and the company remained far from the loss-making year it posted two years earlier.